IMMUNITY TO MELANOMA WITH IL-2-SECRETING ALLOGENEIC CELL
IMMUNITY TO MELANOMA WITH IL-2-SECRETING ALLOGENEIC CELL
批准号:
3200160
负责人:
EDWARD P. COHEN
金额:
$13.71万
依托单位国家:
美国
项目类别:
财政年份:
1992
资助国家:
美国
项目状态:
已结题
起止时间:
1992-04-03 至 1995-03-31
中文摘要
点击翻译按钮获取中文摘要
英文摘要
In spite of the fact that they express immunogenic determinants, B16
melanoma cells grow progressively in immunocompetent C57BL/6 mice (H-2b).
The mechanism of "escape" is not established. Since cytotoxic T
lymphocytes are known to recognize an extraordinarily wide array of small
peptides (in the context of histocompatibility class I), including
neoantigens associated with malignant cells, it may be that the growth of
antigeneic tumors results from a failure of immune recognition, not from
the absence of tumor associated determinants. An understanding of the
cellular "defect" that enables tumor cells to grow in immunocompetent
recipients could have important implications for the specific immunotherapy
of cancer. As an experimental approach, we used transfection to construct
IL-2-secreting, allogeneic mouse fibroblasts that express melanoma
associated antigens. We then tested the cells' immunogenic properties in
terms of their ability to elicit an anti melanoma immune response in mice
syngeneic with the tumor. The construct was prepared by transfecting
genomic DNA from B16 cells (H-2b) into LM cells (H-2k) which are allogeneic
with C57BL/6 mice. Colonies of transfected cells expressing melanoma-
associated determinants were isolated, and then infected with an expression
competent plasmid carrying the gene for IL-2. In our experiments, C57BL/6
mice rejecting the IL-2-secreting, melanoma antigen-positive allogeneic
mouse cells developed cellular immunity to the melanoma. This immunity
exceeded that following immunization with non-IL-2-secreting constructs, or
with B16 cells. The objectives of the proposal are to determine the
specific cell types activated for rejection of B16 melanoma following
immunization of C57BL/6 mice with the IL-2-secreting cell constructs, and
compare them with cell types activated following immunization of mice with
constructs that lack one or more of the immunogenic properties. In
addition, we plan to determine if exogenous IL-2 can substitute for the
direct cell-to-cell (paracrine) transfer of IL-2 in the induction of an
anti melanoma immune response. Finally, we plan to determine if
immunizations of tumor-bearing mice with the IL-2-secreting constructs
leads to increased survival.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
DNA-based Vaccine for Treatment of Oral Carcinoma
-
批准号:6892107
-
项目类别:
-
资助金额:$27.28万
-
财政年份:2003
-
负责人:EDWARD P. COHEN
-
依托单位:
DNA-based Vaccine for Treatment of Oral Carcinoma
-
批准号:6773914
-
项目类别:
-
资助金额:$27.28万
-
财政年份:2003
-
负责人:EDWARD P. COHEN
-
依托单位:
DNA-based Vaccine for Treatment of Oral Carcinoma
-
批准号:7065166
-
项目类别:
-
资助金额:$26.64万
-
财政年份:2003
-
负责人:EDWARD P. COHEN
-
依托单位:
DNA-based Vaccine for Treatment of Oral Carcinoma
-
批准号:6677870
-
项目类别:
-
资助金额:$26.77万
-
财政年份:2003
-
负责人:EDWARD P. COHEN
-
依托单位:
IMMUNITY TO MELANOMA WITH IL-2-SECRETING ALLOGENEIC CELL
-
批准号:2096763
-
项目类别:
-
资助金额:$13.3万
-
财政年份:1992
-
负责人:EDWARD P. COHEN
-
依托单位:
IMMUNITY TO MELANOMA WITH IL-2-SECRETING ALLOGENEIC CELL
-
批准号:3200161
-
项目类别:
-
资助金额:$12.97万
-
财政年份:1992
-
负责人:EDWARD P. COHEN
-
依托单位: